XXXX : Test of utility as a molecular marker in advanced-stage @entity189 .

@entity1 @entity9965 @entity5 @entity957 @entity189 @entity204 @entity22
UNASSIGNED: 5590 Background: @entity9965 is a member of the family of @entity22 ( @entity22 ) proteins that play an important role in the regulation of DNA replication. @entity9965 has been shown to be a proliferation marker in several types of tissue. In this study we examined the utility of the proliferation marker @entity9965 as a molecular prognostic marker in 30 @entity957 . METHODS: Parallel sections of 30 @entity5 were stained with antibodies against @entity9965 . The @entity5 sub-sites were: base of tongue in 11 @entity1 , tonsillar fossa in 13 @entity1 , pharyngeal wall in 5 @entity1 , and faucial arch in 1 @entity1 . The percentage of positively stained nuclei was scored for each antibody. Clinicopathologic @entity1 data were retrospectively collected from medical charts. RESULTS: The average age at presentation was 52 years and 2 months (range 43 - 80 years) in the overall @entity1 population. Twenty-four @entity1 were @entity1 and six @entity1 were @entity1 . Twenty-eight @entity1 (93%) presented with advanced stage (Stage III and IV) disease. There was no significant difference in the proportion of cells stained by anti- @entity9965 between @entity1 who died of the disease and those who remained alive (67.6% versus 62.9%, respectively, p=.74). Similarly, employing a multivariate Cox regression analysis, risk of @entity204 was not found to be associated with elevated @entity9965 expression. These findings did not vary by disease subsite. CONCLUSIONS: Our data suggest that the cellular proliferation marker @entity9965 is of limited clinical utility as a disease prognosticator in individuals diagnosed with advanced stage @entity189 . The role of @entity9965 as a molecular prognosticator in @entity1 with early stage disease requires further investigation. No significant financial relationships to disclose.
